SHANGHAI--(BUSINESS WIRE)--Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice model [LB-018]. These two molecules demonstrated similar tumor growth inhibition (TGI) when they were tested twice.
“It is very exciting to know that orally active small molecule PD-L1 inhibitor has similar efficacy as the PD-L1 antibody drug Durvalumab” commented Dr. Zujun Li, the Clinical Associate Professor of Medicine at New York University and the PI for immunotherapy clinical trials “We are looking forward to the orally active drugs to be added to today’s antibody only therapy.”
About Maxinovel Pharmaceuticals, Inc:
Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com